Form 4: Catalyst Pharmaceuticals CFO Reports Stock Transaction
Insider Transaction (Form 4)
Michael Wayne Kalb, Chief Financial Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
Summary
- Disposition to the issuer: disposed of 13,665 Common Stock, par value $0.001 per share at $31.50 ($430,448) on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 257,214 Options to purchase common stock on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 169,248 Options to purchase common stock on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 131,536 Options to purchase common stock on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 21,416 Restricted Stock Units on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 13,788 Restricted Stock Units on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 39,701 Restricted Stock Units on July 15, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Michael Wayne Kalb — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-15 | Disposition to the issuer | Common Stock, par value $0.001 per share | 13,665 | $32 | $430.4K | 0 |
| 2026-07-15 | Disposition to the issuer | Options to purchase common stock | 257,214 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Options to purchase common stock | 169,248 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Options to purchase common stock | 131,536 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Restricted Stock Units | 21,416 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Restricted Stock Units | 13,788 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Restricted Stock Units | 39,701 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-15 | Disposition to the issuer (13,665 shares) |
| 2026-07-15 | Disposition to the issuer (257,214 shares) |
| 2026-07-15 | Disposition to the issuer (169,248 shares) |
| 2026-07-15 | Disposition to the issuer (131,536 shares) |
| 2026-07-15 | Disposition to the issuer (21,416 shares) |
| 2026-07-15 | Disposition to the issuer (13,788 shares) |
| 2026-07-15 | Disposition to the issuer (39,701 shares) |
Keywords
insider transaction, Form 4, CPRX, CATALYST PHARMACEUTICALS, INC., neutral, Michael Wayne Kalb
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.